Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Nuvectis Pharma Q3 2026 Results: Net Loss of $30.1M, Loss Widens

Nuvectis Pharma reported a significant increase in cash and cash equivalents to $140.7 million as of September 30, 2026, following a substantial equity issuance. However, the company continues to incur losses, with research and development expenses rising to $36.2 million for the first nine months of 2026 compared to $13.1 million in the prior year period.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-30.1-7.5
EPS (diluted, $ a share)$-1.02$-0.44

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: NVCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Nuvectis Pharma, Inc.: key numbers

Share price
$19.11Close, Nov 16
Market cap
$657M
Shares outstanding
34.39MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Nuvectis Pharma, Inc.

All →
7:07 AM ET 8-K
Financial Results

Nuvectis Pharma Financial Results

Nuvectis Pharma reported third quarter 2026 financial results and provided a corporate update following its transformational in-licensing of ex-China rights to NXP100 and NXP200. The company ended the quarter with approximately $140 million in cash, providing a projected runway into the second half of 2029. Management is currently in discussions with the FDA regarding the U.S. regulatory path for ciprocopan (NXP100) in PNH and expects to provide an update by year-end.

“The last few months have been truly transformational for Nuvectis. The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes Nuvectis as a late-stage clinical development company with potential best-in-class assets.”

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis

“With its potential for a clear dosing convenience compared to injectable treatments and Fabhalta—the twice-daily oral CFBi—and supported by robust clinical data in PNH and IgAN as well as validating clinical data from the Fabhalta clinical trials, we believe ciprocopan has the potential to redefine the standard of care for patients in targeted settings.”

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.